Given that the p53-R249S mutation accounts for approximately 26% of all reported p53 mutations in HCC (55, 56), the combined administration of CP-31398 and elesclomol-Cu represents a promising therapeutic approach for the treatment of HCC. The gene discussed is TP53; the disease is hepatocellular carcinoma.